N/A Completed N=29 Randomized Treatment

Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control

Type 2 Diabetes Mellitus

Source: ClinicalTrials.gov NCT01495975 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2015

Primary outcomePrimary: Glycemic Control — 144; 172 mg/dL

Summary

The goal of this research is to evaluate the impact and feasibility of using web-based patient-provider communication and a remote glucose monitoring tool to improve post-hospitalization glycemic control and patient self-care. The investigators hypothesize that providing patients this web-based tool over a 4-week period after discharge to home will result in more effective glycemic control compared to usual care, and that patients with access to the "tool kit" will have a trend towards improved diabetes self-management and less diabetes-related distress.

Outcome Measures

Outcome	Result	p-value
PRIMARY Glycemic Control	144; 172	—
SECONDARY Diabetes Distress	—	—
SECONDARY Diabetes Self-Management	—	—
SECONDARY Unplanned Readmission or ED Visit	—	—

Eligibility Criteria

Inclusion Criteria

Age 18 years or older
English speaking and able to read English
Diagnosis of type 2 diabetes (new and pre-existing)
Hospital admission with endocrinology or inpatient diabetes management consult
On insulin during hospitalization with plan for continuation upon discharge.
Discharge planned for home.
Access to the internet and an active email account throughout the 6-week study period.

Exclusion Criteria

Inability to connect to, navigate, and utilize the web-based system, or designate someone who is capable of using the system.
No identifiable outpatient healthcare provider.
Pregnancy, ruled out by urine hCG test after consent is obtained in all women who continue to have menstrual cycles.
End-stage liver disease with prothrombin time >15 seconds and albumin <3 mg/dL.
Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose <60 mg/dL (tachycardia, diaphoresis, hunger, confusion, fatigue).
Projected survival <1 year.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01495975). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.